In the latest Global Initiative for Asthma (GINA) 2019 guidelines for adults and adolescent, the most important change in asthma management in 30 years has been made.1 For safety reasons, GINA no longer recommends treatment with short-acting beta-agonists (SABA) therapy alone.1 While there is strong evidence that supports